Zoetis Inc. $ZTS Shares Sold by Resources Management Corp CT ADV

Key Points

• Resources Management Corp CT ADV reduced its holdings in Zoetis Inc. by 32.9% in Q1, owning 9,815 shares worth approximately $1.62 million after selling 4,816 shares.
• Zoetis reported $1.76 earnings per share for the last quarter, exceeding estimates and experiencing a 4.2% increase in quarterly revenue year-over-year.
• Analysts have mixed ratings for Zoetis, with four giving a "Buy" rating and four a "Hold" rating, alongside a target price range between $155.00 and $215.00.

Resources Management Corp CT ADV decreased its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 32.9% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 9,815 shares of the company's stock after selling 4,816 shares during the period. Resources Management Corp CT ADV's holdings in Zoetis were worth $1,616,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Teza Capital Management LLC purchased a new position in shares of Zoetis during the 1st quarter worth $457,000. UniSuper Management Pty Ltd increased its stake in Zoetis by 6.1% in the first quarter. UniSuper Management Pty Ltd now owns 33,076 shares of the company's stock valued at $5,446,000 after purchasing an additional 1,900 shares during the last quarter. Select Equity Group L.P. lifted its position in Zoetis by 87.3% during the first quarter. Select Equity Group L.P. now owns 355,331 shares of the company's stock worth $58,505,000 after buying an additional 165,628 shares during the period. Plancorp LLC acquired a new stake in Zoetis in the 1st quarter worth about $268,000. Finally, Nissay Asset Management Corp Japan ADV grew its holdings in Zoetis by 0.3% in the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 59,344 shares of the company's stock valued at $9,771,000 after buying an additional 154 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Up 0.8%

Shares of NYSE:ZTS traded up $1.24 during mid-day trading on Thursday, hitting $150.66. 3,193,909 shares of the company traded hands, compared to its average volume of 3,037,601. The firm's 50 day simple moving average is $152.70 and its 200 day simple moving average is $157.56. The firm has a market cap of $66.77 billion, a P/E ratio of 25.93, a PEG ratio of 2.40 and a beta of 0.89. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same period in the prior year, the firm earned $1.56 earnings per share. The business's quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Analysts Set New Price Targets

ZTS has been the topic of several recent analyst reports. Piper Sandler increased their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Argus reiterated a "buy" rating and issued a $190.00 price target on shares of Zoetis in a report on Tuesday. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partners lowered shares of Zoetis from an "outperform" rating to a "market perform" rating and cut their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Finally, Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Zoetis has a consensus rating of "Moderate Buy" and a consensus price target of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.